中图分类号 R969.4；R541 文献标志码 A 文章编号 1001-0408(2025)11-1375-04

    DOI 10.6039/j.issn.1001-0408.2025.11.15

    ABSTRACT OBJECTIVE To explore the clinical efficacy of dapagliflozin for stable coronary heart disease combined with heart failure(HF). METHODS A prospective study method was employed. A total of 158 patients with stable coronary heart disease and HF admitted to our hospital from January 1，2023，to January 1，2024，were enrolled. Using a random number table method，they were divided into dapagliflozin group ( ) and conventional treatment group n=82 ). All patients received conventional treatment，including diuretic，aspirin，losartan，metoprolol and statins. Patients in the dapagliflozin group were additionally administered Dapagliflozin tablets at a dose of 10mg once daily on top of the conventional treatment. The treatment duration was six months. The changes in left ventricular ejection fraction (LVEF) ......